Citigroup Inc Nuvation Bio Inc. Transaction History

Citigroup Inc

$153 Billion
Q2 2024

A detailed history of Citigroup Inc transactions in Nuvation Bio Inc. stock. As of the latest transaction made, Citigroup Inc holds 727,728 shares of NUVB stock, worth $1.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

727,728

Previous 705,405 3.16%

Holding current value

$1.7 Million

Previous $2.57 Million 17.26%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	BUY	$2.58 - $3.69 $57,593 - $82,371	22,323 Added 3.16%	727,728 $2.12 Million
Q1 2024 May 10, 2024	SELL	$1.46 - $3.97 $511,954 - $1.39 Million	-350,654 Reduced 33.2%	705,405 $2.57 Million
Q4 2023 Feb 09, 2024	BUY	$0.96 - $1.53 $1.01 Million - $1.61 Million	1,054,766 Added 81575.1%	1,056,059 $1.59 Million
Q3 2023 Nov 09, 2023	SELL	$1.26 - $2.1 $87,074 - $145,124	-69,107 Reduced 98.16%	1,293 $1,000
Q2 2023 Aug 10, 2023	BUY	$1.56 - $1.84 $51,364 - $60,583	32,926 Added 87.86%	70,400 $126,000
Q1 2023 May 11, 2023	BUY	$1.6 - $2.48 $33,152 - $51,385	20,720 Added 123.67%	37,474 $62,000
Q4 2022 Feb 09, 2023	SELL	$1.68 - $2.5 $10,908 - $16,232	-6,493 Reduced 27.93%	16,754 $32,000
Q3 2022 Nov 10, 2022	SELL	$0.29 - $4.04 $1,754 - $24,437	-6,049 Reduced 20.65%	23,247 $52,000
Q2 2022 Aug 10, 2022	SELL	$3.24 - $5.85 $28,317 - $51,129	-8,740 Reduced 22.98%	29,296 $95,000
Q1 2022 May 12, 2022	SELL	$4.6 - $8.83 $26,983 - $51,796	-5,866 Reduced 13.36%	38,036 $200,000
Q4 2021 Feb 10, 2022	BUY	$7.75 - $10.05 $111,445 - $144,519	14,380 Added 48.71%	43,902 $373,000
Q3 2021 Nov 10, 2021	BUY	$7.78 - $10.0 $229,681 - $295,220	29,522 New	29,522 $293,000

Others Institutions Holding NUVB

# of Institutions

152

Shares Held

123M

Call Options Held

9.7K

Put Options Held

6.5K

View Full List

About Nuvation Bio Inc.

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $508M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

More about NUVB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.

Account